

# Oncollag

Volume 1, Issue 9, June 24, 2024



https://www.oncologyforum.in/





SN	Content	Page
1.	PRESIDENT'S MESSAGE	3
2.	Oncology Forum	4-5
3.	UICC Membership- A New chapter in Oncology Forum Journey	6-16
4.	Conference Report	17-29
5.	Oncology Forum - Recent Meetings	30-31
6.	Oncology Forum Activity Calendar (January - June 2024)	32
7.	Oncology Forum Heritage Walk	33-35
8.	Oncology Forum Membership	36



# PRESIDENT'S MESSAGE



Prof. SVS Deo
President, Oncology Forum

It is my privilege and honour to serve Oncology Forum as the president. At the outset, I would like to thank all the members of the forum for giving me an opportunity to carry forward the agenda and great efforts as envisaged by our founding members. Oncology Forum was established in 2012 with the main objective to bring all oncologists practicing in the Delhi region together on a single platform to share their knowledge, wisdom, best practices to promote education, research, and high quality patient care. One of the objectives was to facilitate networking and collaboration with reputed national and international oncology societies. The past leadership has successfully organized a number of high quality collaborative academic events. In last 3 years, some important initiatives taken by Oncology Forum-

- Collaborative Research
- •UICC Membership and participation in World Cancer Leader's Summit
- •Life Time Achievement Awards during OFCON
- •Successful theme based annual conferences
- Awards to students during annual conference
- Oncology Forum presence in 3rd Indian Cancer Congress
- Students web based interactive classes and lecture series
- Membership drives
- Our door interactive and networking activities

I would like to salute and thank to entire oncology community of NCR Delhi region for their support and active participation in Oncology Forum activities and making them grand success.

Regards & Best wishes

Prof. SVS Deo

President, Oncology Forum



# **Oncology Forum**

Dr. G.K.Rath



AIIMS, New Delhi



**PATRONS** 

Dr.(Col.) R. Ranga Rao Paras Hospital, New Delhi



Dr. Harit Chaturvedi Max Hospital, Delhi



Dr. P.K. Julka Max Hospital, Delhi



Dr. Shyam Aggarwal Sir Ganga Ram Hospital, Delhi



Dr. D.C.Doval RGCIRC, Delhi



Dr. Arvind Chaturvedi RGCIRC, Delhi



Dr. A.K. Anand FMRI, Gurugram



Dr. A.K. Vaid Medanta Medicity, Gurugram

## **ONCOLOGY FORUM OFFICE BEARERS**



Dr. SVS Deo President



Dr. Geeta Kadayaprath



Dr. Vineeta Goel Secretary



Dr. Kanika Sood Joint Secretary



Dr. Rudra Acharya Treasurer



Dr. Ashutosh-Mishra UICC Coordinator & **EC** Member



# **EXECUTIVE COMMITTEE MEMBERS**



**Dr. Sowrabh Arora** Max Superspeciality Hospital, Vaishali



Dr. Ashish Goel Jaypee Hospital, Noida



Dr. Devavrat Arya Max Superspeciality Hospital, Saket



Dr. Babul Bansal AIIMS, Delhi



**Dr. Navin Kumar Gupta** AIIMS, Delhi



Dr. Dodul Mondal Max Superspeciality Hospital, Saket



**Dr. Akshat Malik** Max Superspeciality Hospital, Saket



**Dr. Amit Verma**Max Superspeciality
Hospital, Saket



**Dr. Shubham Garg**Fortis Hospital,
Noida



# UICC Membership - A New chapter in Oncology Forum Journey

-Dr Ashutosh Mishra

Over one decade, Oncology Forum has become an independent and dynamic association of Oncologists in Delhi NCR. Currently, it has more than 350 life members. In last one decade, Oncology form has hosted successfully First Indian Cancer Congress in 2013 and created a history. Since then Oncology Forum has hosted many National conferences and helped hundreds of oncologist in conducting their conferences. Hence, it was the time to take a step ahead and make our presence at global platform as well. Dr SVS Deo, President surgical oncology raised this agenda of UICC Membership and which was wholeheartedly supported by entire current and past oncology forum leadership. OF Executive committee decided that Dr Ashutosh Mishra, Executive member Oncology Forum will pursue the UICC membership agenda. First meeting for UICC Membership with Muriel Auclair, Membership Manager held at Geneva during World Cancer Congress, 2022, subsequently all the relevant documents submitted to UICC and we got UICC Membership status in March 2023.





### Why this UICC Membership is so important for Oncology Forum?

UICC is world's largest association fighting against cancer and we as an organization has same motto and targets. UICC provides membership to worlds reputed organizations who can come together in this unique fight against cancer. UICC has more than 1200 member from 172 different countries and it has more than 60 partners like WHO, UNICEF, IARC, ACS IAEA, UNODC, United Nation economic and sociabouncil etc.



UICC help us in connecting people across the globe and provide an opportunity to convey our message to rest of the world including WHO and United Nations. UICC's network brings together cancer societies, patient support groups, research and cancer centres, nongovernmental organizations (NGOs), grassroots organizations, professional associations and government agencies shaping cancer control everywhere in the world. So, We as a member of Oncology Forum can get connected with different global communities and can come forward for the control of cancer.









### Combination of Global – Regional approach

In order to better respond to the needs of UICC members andregional differences, UICC has developed a regional approach to tailor the capacity building offer, adapting and facilitating access as appropriate, or developing key activities for the cancer control community when needed. The regionalisation of UICC activities is a cross cutting approach being pursued through:

- Adapting the capacity building offer based on UICC's network of experts at the country level to ensure that opportunities are relevant, responsive and address specificities and needs of each region.
- Making opportunities accessible to all members, through targeted promotion, accompaniment and translation, thus overcoming previously existing barriers.
- **Developing** new activities when a concrete need in the region is identified, or a gap or low uptake of existing opportunities in specific regions.



## ■ UICC's learning and development opportunities

Online learning- UICC's online learning offer includes a dedicated <u>eLearning platform</u> hosting a range of on-demand and live learning opportunities on multidisciplinary topics in cancer control. Through its online learning offer UICC aims to provide evidence based knowledge on key multidisciplinary topics related to global cancer control, as well as providing opportunities for UICC members to connect with and learn from each other through interactive live sessions and discussion activities.



- **UICC Fellowships** UICC's Fellowships aim to strengthen workforce capacity in <u>cancer control</u> by supporting individual in -person short-term international visits with leading experts and institutions to gain technical knowledge and tailored advice.
  - Technical Fellowships- UICC's Technical Fellowships provide cancer professionals the chance to gain new knowledge, skills and techniques in cancer control through short learning visits of two weeks to two months' duration. This specific fellowship opportunity was originally launched in 1976, and was called the International Cancer Research Technology Transfer awards (ICRETT), and has facilitated knowledge exchange for the last four decades.



### Practical Information

Duration	Flexible durations of two weeks to two months
Extension	Up to two months, with no further funding available from UICC
	<ul> <li>Two weeks - 2,200 USD*</li> <li>Three weeks - 2,800 USD*</li> <li>Four weeks - 3,400 USD*</li> </ul>
Duration of Technical fellowship with maximum level of funding possible	• Five weeks - 4,000 USD*
	<ul><li>Six weeks - 4,600 USD*</li><li>Seven weeks - 5,200 USD*</li></ul>
	• Eight weeks - 5,800 USD*

Virtual Fellowships - Virtual Fellowships allow cancer professionals from <u>UICC member organisations</u> to obtain expert learning and guidance in cancer control in English, French or Spanish, through a series of four one -to-one video calls with experts. Fellowship Conditiion-

Call timeframe	Apply any time from 1 February to 31 December 2024.
Target candidates	Cancer professionals working in research, public health or health service delivery at UICC member organisations.
Experts	If needed, UICC can provide support in identifying and contacting experts.
Duration	One month: minimum of four weekly one-hour video calls. Start date flexible, to be agreed upon with expert.
Eligibility	Eligible candidates must be employed by a UICC member organisation (students are not eligible), have the endorsement of their line manager/superior and at least five years' experience working in cancer control.
Average value	No specific funding will be provided for those awarded a Virtual Fellowship.
Fellowship topics	All applications in cancer control are welcome, please see the list of recently completed fellowships for examples of fellowship topics. While candidates working in all fields of cancer control are welcome to apply, applications in breast cancer (as part of the broader Breast Cancer Programme) and cancer and ageing are particularly encouraged this year.



o **YY Study Grants -** The YY Study Grants provide an important opportunity to advance cancer research through international collaboration. Their purpose is to enable individuals from any country to carry out cancer research projects abroad and including the opportunity to receive further training in research methods or techniques. Since its inception in 1972, the YY Study Grant programme has contributed to the professional capacity development of over 330 Fellows from over 40 countries.

**Eligible Candidates -** Possess PhD (or <u>equivalent degree</u>\*) at least 2 years prior to the application closing date of the YY Selection applied for

- Actively engaged in cancer research
- Recent publications in the international peerreviewed literature

### **Practical information:**

Target candidates: Researchers, clinicians, epidemiologists, public health professionals

**Duration:** Three months

Extension: Up to two months with funding secured by the fellow from other sources and at no cost to UICC

Available: Four to five YY Study Grants

Average value: US\$ 10,000

Research type: Basic, translational, public health or applied cancer research

■ **Grants-** UICC regularly offers cancer organisations globally with opportunities to access seed -funding and project grants addressing key gaps and needs in cancer control.

Since 2016, UICC has awarded close to US\$ 2.5 million in grants to 100+ organisations in the cancer community, mostly in the area of women's cancers (both breast and cervical), humanitarian assistance for cancer patients, older adults with cancer and <a href="mailto:childhood:cancer">childhood:cancer</a>.





workstream leverages UICC platforms and catalyses external expertise to strengthen the leadership, management and organisational know -how of the UICC membership. The workstream builds on flagship initiatives, such as the Young Leaders programme and the CEO Programme, expanding the approach through a refreshed combination of virtual and in-person learning and networking opportunities aimed at leaders across multiple levels, whether seasoned CEOs or emerging managers, patient advocates or healthcare executives, scientists in the lab or health practitioners on the frontline.



Cancer Advocate Programs - The Cancer Advocates programme provides opportunities for civil society organisations in low - and middleincome countries to gain the skills and knowledge to engage in national advocacy efforts for improved cancer control.





- Patient Group Mentoring Programme The Patient Group Mentoring programme offers peer-to-peer support, accompaniment and connections to select regional cohorts of patient-driven organisations.
- **Master courses** Master courses are cohort -based courses purpose-built by internationally recognised experts addressing priority subjects in cancer control through a blend of modular learning and peer-exchange.
- UICC eLearning Platform- Free for Members



#### Welcome to UICC eLearning

The Union for International Cancer Control (UICC) unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control continues to be a priority in the world health and development agenda.

The UICC eLearning offer provides cancer control professionals with access to specialised knowledge and expertise by internationally recognised leaders in their field on priority topics in cancer control. The learning on offer includes both faculty-led, scheduled Master courses and on-demand self-guided courses.

#### **Accessing UICC online courses**

- Employees of UICC member organisations have unlimited free access to all self-guided courses on the platform
- Individuals who are not employed by a UICC member organisation can purchase courses and gain access to the content for a sixmonth period. Product bundles are available which provide discounted access to a collection of courses focusing on a specific theme.



### **UICC Awards- For Member organisations**

To maximise the impact of our collective efforts or global cancer control, it is important to learn from the many examples of leaders, campaigners, advocates and fundraisers from across the cancer community.

The UICC awards aim to identify and celebrate the contributions made by professionals and organisations from the UICC membership and inspire the cancer control community through their efforts.

Open to UICC members only, nominations are sought on World Cancer Congress years in a number of categories for the chance to be recognised at a dedicated award ceremony, normally held at the World Cancer Congress.

First launched on the occasion of the 2018 World Cancer Congress, the UICC awards have recognised individuals, organisations and projects in a range of different categories.



**UICC Newsletters** - UICC's monthly newsletter offers a mix of content, including news and blog articles, opportunities for members, useful resources and much more. It provides its members a platform to show their work across the globe.



Union for International Cancer Control

## **Monthly Newsletter**

March 2024

# UICC welcomes and supports renewed commitments to bridge gaps in care for women's cancers






#### **UICC Events -**

UICC unites cancer professionals and policy makers in premier events like the **World Cancer Congress** and **World Cancer Leaders' Summit** and raises awareness and catalyses personal, collective and government action through **World Cancer Day**.

- Discounted rates for Members
- Opportunity to host a session during World Cancer Congress.
- Invitation for World Cancer Leader's Summit
- Participation as a lead in World Cancer day.





# **Conference Report**

# 6<sup>th</sup> Annual Conference of Oncology Forum, Delhi OFCON 2023



Oncology Forum represents Delhi-NCR oncologists including surgical, medical, radiation oncologists, onco-pathologists, onco-radiologists, psycho-oncologists & onco-anesthesiologists. Oncology Forum is committed to bring Delhi- NCR oncologist on a single platform to standardize the oncology practice in the community and on that path, we were able to attain the same in last one decade. Under the aegis of Oncology forum, we have successfully conducted many national conferences like ICC 2013, IASO NATCON 2021 and left a meaningful impact on oncology community. This year Oncology forum has also become the member of UICC (Union for Cancer Control) and contributing to world cancer care.

"Impact of Molecular Oncology & Real-World Practice" was the theme of 6<sup>th</sup> annual conference of Oncology Forum.



Molecular oncology as an interdisciplinary domain has evolved significantly in last two decade. In this duration molecular oncology research has traveled a lot from bench to bedside and compelling us to review again, our concept about cancer chemistry at molecular level and their diagnostic and therapeutic implications. Molecular oncology advancement not only incorporated targeted and immunotherapy in cancer treatment but also able to modify surgical decisions. Hence, this conference was completely dedicated to organ specific molecular oncology and the scientific program was designed to review the impact of molecular oncology on real life practice.

The OFCON 2023 was organized at the The Lalit, New Delhi from December 2-3, 2023, with the theme "Impact of Molecular Oncology & Real-World Practice". Approximately 300 delegates from different backgrounds attended this conference.

#### **Conference Highlights**

- One and Half day scientific extravaganza
- More than 130 faculties from Delhi and North India
- 300+ delegates including basic science researchers, clinicians, pathologists, precision oncologist etc.
- Dedicated 16 hours on molecular oncology
- Oncology Forum research update
- Organ specific sessions- Head & Neck, Breast, Gl, Lung, Gynae
- Multi-disciplinary discussion on challenging cases
- Oncology Forum session- challenges and opportunities in Delhi-NCR
- UICC session for global cancer perspective and opportunities
- Lifetime achievement award to NCR renowned oncologist.
- Abstracts and Awards
- Networking Sessions
- Gala dinner





### **OFCON 2023- Oncology Forum Life time achievement Awards**

The Oncology Forum Office bearers and executive committee decided to give "Oncology Forum Life time achievement Award" to three members who has done incredible work in the field of Oncology All three awardees were awarded during inaugural ceremony of OFCON 2023 at The Lalit.

#### Awardees-

Dr (Col) Ranga Rao Rangaraju, VSM, MD, DM
 Chairman, Paras Cancer Centres,
 Paras Hospitals, Gurgaon, India



2. Prof Nootan K Shukla, MS, FACS Former Haed Dept. of Surgical Oncology, AIIMS, New Delhi



3. Dr Aravind Chaturvedi, MBBS, MD

Chair Emeritus of Radiology
and Interventional Oncology,
Rajiv Gandhi Cancer Institute, NewDelhi



















# **OFCON 2023- Scientific Program**

**OFCON-2023** 







6th Annual Conference of Oncology Forum, Delhi
IMPACT OF MOLECULAR ONCOLOGY & REAL-WORLD PRACTICE

and the second of the second		2nd December 2023				
Timing		Session	Speaker			
0830Hrs	Registration					
0900-0925Hrs	Mastervideos					
0925-1105Hrs	Session-1: Oncology Forum Research Update					
	Chairperson: Prof SVS Deo, Prof Sandeep Mathur, Dr Naveen Gupta, Dr Mahendra Pal Singh					
	0925-0930 Hrs	Overview & Introduction	Prof SVS Deo			
	0930-0940Hrs	Amity University	Dr Ujjaini Dasgupta			
	0940-0950Hrs	AIIMS, New Delhi- Basic Science	Dr Ashok Sharma			
	0950-1000Hrs 1000-1010Hrs	CSIR-IGIB- Institute of Genomics & Integrative Biology  Max Institute of Cancer Care	Prof Shantanu Chowdhury			
	1010-1010Hrs	AIIMS New Delhi - Oncopathology (Lung)	Dr Atul Thatai Prof Deepali Jain			
	1020-1030Hrs	RGCI	Dr Anurag Mehta			
	1030-1040Hrs	AIIMS, New Delhi- Lab Oncology	Dr Mayank Singh			
	1040-1050Hrs	Art of Healing Cancer (AOHC)	Dr Mandeep Singh Malhotra			
	1050-1105Hrs	CTC based Tumor Viability and Transcriptomic analysis: Concept	Dr Ioannis Papasotiriou, RGCC, Europe			
1105-1125Hrs		Tea Break				
1125-1145Hrs		Session 2: Molecular Imaging				
		Chairperson: Dr Rudra P Acharya, Dr Naveen Sanchtey, I	Or Rashi Agarwal			
	1125-1145Hrs	Molecular Imaging - Basics & Updates	Dr Rakesh Kumar, AIIMS			
1145-1300Hrs		Session 3: Head & Neck Oncology				
		Chairperson: Dr Pradeep Jaiswal, Dr Jyoti Sharma, Dr Su				
	1145-1155Hrs	Molecular markers on thyroid cancer: Where are we now?	Dr Sowrabh Arora, Max Hospital			
	1155-1205Hrs	Biomarkers in Head and Neck squamous cell carcinoma.	Dr Ashish Goel, Jaypee Hospital			
		Chairperson: Prof Rakesh Arora, Dr Sowrabh Arora, Dr				
			Panelist -			
			Dr Akshat Malik, Max Saket, SO Dr Mandeep Singh Malhotra, AOHC, SO			
			Dr Aman Sharma, NCI, RO			
	1205-1250Hrs	Case Based Panel Discussion - Molecular testing and Head and Neck	Dr Munish Gairola, RCGI, RO			
		Cancers - Dr Deepak Sarin, Medanta (Moderator)	Dr Vikas Goswami, Max Vaishali, MO			
			Dr Mukesh Patekar, Artemis, MO			
			Dr Hemamalini Iyer, Molecular Pathology			
			Dr Sanjay Meena, NCI, Radiology			
1250-1335Hrs		Lunch				
1335-1510Hrs	Session-4: Breast Oncology Chairperson: Dr Kapil Kumar, Dr Deepak Jha, Dr Ashutosh Mishra					
	1335-1345Hrs	Molecular subtype- impact on breast cancer surgery	Dr Arun Goel, SO, Andromeda			
	1345-1400Hrs	Targeted and Immunotherapy in localised breast cancer	Dr Atul Batra, AllMS, MO			
	1400-1410Hrs	De-escalation strategies in Her 2 Neu positive Breast Cancer	Dr Aditi Chaturvedi, Max. SO			
	1400-14101113		Di Aditi Giatti Vetti, Max, 30			
		Multi-marker tests for recurrence risk prediction in HR+ EBC - "Can				
	1410-1425Hrs	Multi-marker tests for recurrence risk prediction in HR+ EBC - "Can Assist Breast (CAB) data" (Zydus)	Dr Rohan Khandelwal			
	1410-1425Hrs	Assist Breast (CAB) data" (Zydus)				
	1410-1425Hrs					
	1410-1425Hrs	Assist Breast (CAB) data" (Zydus)	nushree Vartak Panelist - Dr Tripti Saxena, Fortis Noida, RO			
	1410-1425Hrs	Assist Breast (CAB) data" (Zydus)	nushree Vartak Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO			
		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A	nushree Vartak Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO			
	1410-1425Hrs 1425-1510Hrs	Assist Breast (CAB) data" (Zydus)	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditt Chaturvedi, Max Saket, SO			
		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO			
		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO			
		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology			
1510-1650Hrs		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditt Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine			
1510-1650Hrs		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine			
1510-1650Hrs		Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine			
1510-1650Hrs	1425-1510Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report – Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine  a, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report – Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine  a, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamallini Iyer, Dharmshila Hospital			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report - Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Agiendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine Da, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Aparna Dhar, Max, Precision Oncology			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report – Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditt Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Aparna Dhar, Max, Precision Oncology Dr Shubham Jain			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report - Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajvoti Das, NCI, Nuclear Medicine  a, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Aparna Dhar, Max, Precision Oncology Dr Shubham Jain  Panelist			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report – Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes  Chairperson: Dr Geeta Kadayaprath, Dr Rudra P Acharya	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Apama Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine  a, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Aparna Dhar, Max, Precision Oncology Dr Shubham Jain Panelist Dr Arun Kumar, Roche			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report - Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes  Chairperson: Dr Geeta Kadayaprath, Dr Rudra P Acharya  Panel Discussion - Selecting NGS panels and what not to miss in a NGS	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine Da, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Aparna Dhar, Max, Precision Oncology Dr Shubham Jain Panelist Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs 1555-1610Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report – Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes  Chairperson: Dr Geeta Kadayaprath, Dr Rudra P Acharya	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditt Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital Dr Hemamalini Iyer, Dharmshila Hospital			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs 1555-1610Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report - Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes  Chairperson: Dr Geeta Kadayaprath, Dr Rudra P Acharya  Panel Discussion - Selecting NGS panels and what not to miss in a NGS	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditi Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine  a, Dr Aparna Sharma Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Aparna Dhar, Max, Precision Oncology Dr Shubham Jain Panelist Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital Dr Hemamalini Iyer, Dharmshila Hospital			
1510-1650Hrs	1425-1510Hrs 1510-1525Hrs 1525-1540Hrs 1540-1555Hrs 1555-1610Hrs	Assist Breast (CAB) data" (Zydus)  Chairperson: Dr Shyam Agarwal, Dr Ramesh Sarin, Dr A  Case based Panel Discussion- Molecular testing and Breast Cancers -  Dr Geeta Kadayaprath, Max Hospital (Moderator)  Session-5: Molecular Oncology Worksho Chairperson: Dr Pranay Tanwar, Dr Mandeep Singh Malhotr What to look for in a CGP report - Live workshop (Roche) Predictive Biomarkers: Steering Immunotherapy Decisions The Liquid Symphony: Harmonizing Precision Medicine with Liquid Biopsy Genetic testing for hereditary cancer syndromes  Chairperson: Dr Geeta Kadayaprath, Dr Rudra P Acharya  Panel Discussion - Selecting NGS panels and what not to miss in a NGS	nushree Vartak  Panelist - Dr Tripti Saxena, Fortis Noida, RO Dr Kuldeep Sharma, Venkateshwara, RO Dr Rajendra Saggu, Max Vasihali, SO Dr Aditt Chaturvedi, Max Saket, SO Dr Tanvi Sood, Paras Hospital, MO Dr Sumant Gupta, Metro, MO Dr Aparna Dhar, Max, Precision Oncology Dr Kalpajyoti Das, NCI, Nuclear Medicine Dr Arun Kumar Dr Moushumi Suryavanshi, Amrita Hospital Dr Hemamalini Iyer, Dharmshila Hospital Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital Dr Arun Kumar, Roche Dr Moushumi Suryavanshi, Amrita Hopsital Dr Hemamalini Iyer, Dharmshila Hospital			



# OFCON-2023 6th Annual Conference of Oncology Forum, Delhi IMPACT OF MOLECULAR ONCOLOGY & REAL-WORLD PRACTICE







700-1805Hrs	Session-6: Gy nae Oncology				
	Chairperson: Dr M D Ray, Dr Babul Bansal, Dr Pushpinder Gulia				
	1700-1710Hrs	ESGO ESMO Asian guidelines and consensus on cancer endometrium management and new staging incorporation	Dr Vineeta Goel, RO, Fortis		
	1710-1720Hrs	Role of HRD in ovarian cancer	Dr Rajat Saha, MO, Max Hospital		
	1720-1730Hrs	Genetic testing in Gynecological cancers	Dr Rama Joshi, GO, Fortis Hospital		
		Chairperson: Dr S Hukku, Dr Abhishek Shankar, D	Panelist -		
	1730-1805Hrs	Case based Panel Discussion- Molecular testing and Gynecological Cancer - Dr Swarupa Mitra, Fortis, RO (Moderator)	Dr Kanika Gupta, Max Vaishali, GO Dr MD Ray, AIIMS, SO Dr Peush Bajpai, Manipal, MO Dr Seema Singh, Yashoda Hospital, SO Dr Manoj Tayal, Max PPGJ, RO Dr Karun Kamboj, NCI RO Dr Babita Kataria NCI, MO Dr Kalpajyoti Das, NCI, Nuclear Med		
805-1845Hrs		Session -7: Challenges for Molecular Oncology in T			
		Chairperson: Dr Harit Chaturvedi, Dr R Ranga Rao, I			
	1805-1845Hrs	Panel Discussion - Molecular on cology practise & challenges in tier 2/3 cities - Dr Ashish Jakhetiya, Udaipur (Moderator)	Panelist- Dr Pankaj Garg, Dehradun, SO Dr Paras Khanna, Jammu, SO Dr Than Singh Tomar, Mathura, SO Dr Raman Kain, Gwalior, MO Dr Jitender Rohilla, Chandigarh, SO Dr Rajpal Singh, Jammu, RO Dr Tushar Agarwal, Agra, Pathology		
845-1900Hrs		Inaugural Ceremony			
900-1915Hrs		Oncology Forum Session: Oncology Forum Lifetime Achieve	ment Award Ceremony		
		UICC updates			
915-1945Hrs		Oncology Forum GBM			
		3rd December 2023			
Timing		Session Session	Speaker		
830-0930Hrs		Free Paper Session			
		10 best oral presentation (5+1) x10	American American		
930-1100Hrs	Session-1: GI Oncology				
		Chairperson: Dr V P Singh, Dr Sanjeev Kumar, Dr S			
	0930-0940Hrs	Precision Oncology in esophageal cancer	Dr Kanika Sood, Narayana Hospital		
	0940-0950Hrs 0950-1000Hrs	Precision Oncology in pancreatic cancer Precision Oncology in Colorectal Cancer	Dr Sandeep Bhoriwal,AIIMS Dr Vedant Kabra,Fortis FMRI		
	0950-1000HIS	Chairperson: Dr D N Sharma, Dr Vedant Kabra, Dr			
	1000-1045Hrs	Case Based Panel Discussion- Molecular testing and GI Cancers - Moderator - Dr Atul Sharma, Max Hospital  Monitoring MRD in Colorectal Cancer to Advance Precision Medicine	Panelists Dr Gagan Saini, Max Vaishali, RO Dr Rudra P Acharya, Paras Hospital, SO Dr Abhishek Aggarwal, RGCI, GI Onco Dr Shikha Halder, BLK Hospital, RO Dr Dodul Mandal, Max Hospital, RO Dr Tapan Chauhan, Artemis Hospital, SO Dr Randeep Singh, Narayana Hospital, MO Dr Shefali Sardana, Max Hospital, MO Dr Aparna Dhar, Max, Precision Oncology Dr Prince Das, AlIMS, Radiology		
	1045-1100Hrs	(Zydus)	Dr Shefali Sardana,Max, MO		
100-1115Hrs		Tea Break	•		
115-1235Hrs		Session-2: Thoracic Oncology			
	1115-1125Hrs	Chairperson: Dr LM Darlong, Dr Bhushan Thombare, D Perioperative immunotherapy in NSCLC- Is it increasing Resectability?	r Amitabha Mandal Dr Subham Garg, Fortis Hospital		
		Biomarkers and testing strategies for optimising the selection of thera			
	1125-1135Hrs	in Lung cancer	Dr Durgatosh Pandey, Manipai Hospitai		
	1135-1145Hrs	Adjuvant Strategies in Driver mutation in NSCLC	Dr Peush Bajpai , Manipal Hospital		
	1145-1155Hrs	Role of Atezolizumab in adjuvant NSCLC (Roche)  Chairperson: Dr Rudra P Acharya, Dr Raghuram K, Dr	Dr Randeep Singh, Narayana Hospital		
	1155-1235Hrs	Case based panel Discussion-Molecular testing and Lung Cancers - Dr Ullas Batra (Moderator)	Panelist - Dr LM Darlong, RGCI, SO Dr Charu Garg, Max Saket, RO Dr Anurag Mehta, RGCI, Oncopathology Dr Deepam Pushpam, AIIMS, MO Dr Gogi Ramana Murthy, FMRI, MO Dr Aman Sharma, NCI, RO		



# OFCON- 2023 (\*)







1235-1315Hrs	Session-3: Panel Discussion - Haemato-oncology				
	Dr Akash Jha, Dr Jasmita Das, Dr Sumant Gupta				
		Case Based Panel Discussion - Haemato-oncology - Dr Prashant Mehta, Amrita Hospital (Moderator)	Panelist - Dr Mukul Aggarwal, AIIMS, Hematologist Dr Pradeep Kumar, MO Dr Depam Pushpam, AIIMS, MO Dr Abehishek Raj, Sarvodaya Dr Ankur Nandan Varshney, VMMC & Safdarjung, MO		
1315-1330Hrs	Valedictory Function				
1330Hrs onwards	Lunch				

# **OUR SPONSORS**













## **Maahi Enterprises**





OFCON 2023 Session-Molecular oncology Challenges in tier 2-3 cities.






OFCON 2023 Session Molecular gynecologic oncology
Panel Discussion

OFCON 2023 Session -Molecular GI oncology Panel Discussion





## **OFCON 2023- UICC Session**















## **OFCON 2023- Awards**

# OFCON Best Oral Papers (Cash Prize)

S.No.	Position	Name	Email	Abstract Title
1.	Ist Position	HEMA SIRI KOTTU	hema.siri3@gmail.com	PREDICTIVE AND PROGNOSTIC VALUE OF CELL-FREE DNA IN PLASMA AND PLEURAL LAVAGE AMONG SURGICALLY TREATED ADENOCARCINOMAS (ADCL) OF THE LUNG
2.	2nd Position	RISHABH ARORA	rishabharora0987@gmail.com	TOXICITY ANALYSIS OF CHEST WALL ABUTTING LARGE PRIMARY LUNG TUMORS TREATED WITH SBRT: DOSIMETRIC ASSESSMENT AND CLINICAL OUTCOMES
3.	3rd Position	BHAWANI PATHAK	bhawanipthk@gmail.com	IS INCIDENTAL GALL BLADDER CANCER IN ENDEMIC REGION TRULY INCIDENTAL? - LONG-TERM ONCOLOGICAL OUTCOMES OF INCIDENTAL GALL BLADDER CANCER PATIENTS FOLLOWING CURATIVE RESECTION
4.	Best Oral	PREETI GREWAL	pgrewal1650@gmail.com	A STUDY OF THE IMMEDIATE PATIENT RELATED OUTCOMES USING THE BREAST QUESTIONNAIRE (BREAST Q) IN BREAST CANCER PATIENTS UNDERGOING NOVEL AACAP FLAP ONCOPLASTY PROCEDURE
5.	Best Oral	RAJA BHAGAT CHANDRA CHOWDARY GARAPTI	rajabhagat1@gmail.com	RISK FACTORS FOR SUPERIOR MEDIASTINAL LYMPH NODE METASTASIS IN PAPILLARY THYROID CANCER
6.	Best Oral	BITTU BHUKKAL	bhukkal09@gmail.com	DEMOGRAPHIC PROFILE THE PATTERN OF RECURRENCE AND SURVIVAL ANALYSIS OF 123 GASTROESOPHAGEAL JUNCTION TUMORS
7.	Best Oral	RITIKA BHANDARI	ritikabhandari8493@gmail.com	WIRE IN MIRE!! EFFICACY OF PREOPERATIVE WIRE LOCALIZATION OF IMPALPABLE BREAST LESIONS IN A SINGLE BREAST UNIT AT A TERTIARY CARE CENTER
8.	Best Oral	GURPREET SINGH BEHL	gurpreetsingh211992@gmail.com	-

# OFCON Best Posters (Cash Prize)

S.No.	Position	Name	Email	Title
1.	Ist Position	MOHAMMED NAFEES ANSARI	ansari.nafees@nii.ac.in	RICTOR DRIVES ZFX-MEDIATED GANGLIOSIDE BIOSYNTHESIS TO PROMOTE BREAST CANCER PROGRESSION
2.	2nd Position	GURPREET SINGH BEHL	gurpreetsingh211992@gmail.com	DO ALL THE GALL BLADDER CANCER PATIENTS WITH STAGE IV HAVE SIMILAR OUTCOMES? AND PROGNOSTIC FACTORS AFFECTING THE SURVIVAL OF SURGICALLY TREATED GALL BLADDER CANCER PATIENTS
3.	3rd Position	ARTI MEHROTRA	aartidr.23@gmail.com	UNUSUAL RESPONSE TO UNCOMMON DISEASE TEENAGER WITH EPITHELIOID GLIOBLASTOMA MULTIFORME



# OFCON 2023- Glimpse



































ONCOLOGY FORUM

## **Oncology Forum - Recent Meetings**



DELHI GI ONCOLOGY GROUP
DELHI THORACIC ONCOLOGY GROUP
DELHI STEREOTAXY GROUP

Save the Date 14th March, 2024 6.30 pm - 9.30 pm India Habitat Centre Delhi Magnolia Hall

#### Topic:


1. Perioperative Immunotherapy in GI Oncology: Recent Updates 2. Present and future of multimodality strategies in Stage I-III Non-small cell lung cancers 3. SBRT in Hepatocellular Carcinoma: How and When?


# Organisers Convenors:


- 1. DGIOG
- 2. DTOG
- 3. DSG
















# Oncology Forum Activity Calendar January – June 2024

DATE TIME	PLACE			ORGANIZING SECRETARY	Topic
		EXECUTIVE COMMITTEE MEETING	ACADEMIC MEETING		
17.01.2024	Zoom	EC Meeting		Ms. Nidhi Mittal	
21.02.2024	Virtual Zoom		DTCTG Lecture 1	Dr. Prashant Mehta	Clinical aspects of CAR-T cell therapy in Lymphoma
10.03.2024.	Chandni Chowk	-	Oncology Forum Heritage Walk	Ms. Nidhi Mittal	
14.03.2024.	India Habitat Centre, Delhi		OF MIDCON – 1 DGIOG DTOG DSTOG	Convenors of DGIOG DTOG DSTOG	1.Perioperative Immunotherapy in GI Oncology: Recent Updates 2. Present and Future of multimodality strategies in Stage 1-3 Non-small cell lung cancers 3. SBRT in Hepatocellular Carcinoma: How and when?
20.03.2024.	Zoom		DTCTG Lecture 2	Dr. Prashant Mehta	Indications of Allogenic HSCT in AMI in the genomic era
12.04.2024.	Zoom		DHNOG Interactive class	Dr. Shilpi Sharma	Management of lower alveolus carcinoma
04.05.2024	Medanta Hospital Gurugram		DUOG	Dr. Shyam Bisht	Renal Cell Carcinoma Surgery Ablation, SBRT & Systemic Therapies
06.05.2024	Zoom	EC Meeting		Ms. Nidhi Mittal	
10.05.2024.	Zoom		DGOG	Dr. Neha Kumar	INDIGO: Introspections & Deliberations in Gynecologic Oncology
28.06.2024	IHC		OF MIDCON 2 DHNOG DNOG DMSOG	Dr. Sowrabh Arora Dr. Aditi Aggarwal Dr. Vivek Verma	-



## **Oncology Forum Heritage Walk**

Taking care of our dedicated doctors' wellbeing with a rejuvenating heritage walk through the bustling streets of Delhi's Chandni Chowk! It's time to unwind,

explore, and appreciate our city's rich history while fostering camaraderie and relaxation. #HeritageWalk #OncologyForum



























## **Oncology Forum Membership**



2. UICC Membership

3. Participation in ICC

4. OnkoMag to share your voice

MORE INFO 9350403142

Life Time Membership for INR3000

## **Special Offer for Students**

Life Time Membership for INR 1500 only

Membership form is on website www.oncologyforum.in

## **Oncology Forum**

Registered Address : *B-4/262*, *Safdarjung Enclave*,

New Delhi

Email: <u>oncologyforum1@gmail.com</u> Phone: 011 - 42334196, 9350403142